Diabetes/Obesity Publications

Manuscripts

Lynch CJ et al. Some cannabinoid receptor ligands and their distomers are direct acting openers of SUR1 K-ATP channels. Am J Physiol Endocrinol Metab 2011  Dec 13. Epub ahead of print.

Vickers SP et al. The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol 164: 1248-1262, 2011.

Heal D et al. The 5-HT₆ receptor as a target for developing novel antiobesity drugs. In: International Journal of Neurobiology, Vol 96, F Borsini (Ed), Academic Press, pp 73-109, 2011.

Heal DJ et al. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol 68: 861-874, 2009.

Heal DJ et al. Selective 5-HT₆ ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.  Pharmacol Ther 117: 207-231, 2008.

Vickers SP and Cheetham SC. Preclinical developments in anti-obesity drugs.  In: Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs, T Kirkham and S Cooper (Eds), Academic Press, pp 323-336, 2007.

Posters

Grempler et al. The novel SGLT-2 inhibitor BI 10773 (empagliflozin) prevents pioglitazone-induced weight gain and further improves glycemic control in dietary-induced obese rats. Abstract No. 1851-P. American Diabetes Association 71st Scientific Sessions, San Diego, California, 24th-28th June 2011.  View poster

Lynch CJ et al. Potential role of direct K-ATP channel opening in the anti-diabetic actions of rimonabant and ibipinabant. Abstract No. 2011-P. American Diabetes Association 71st Scientific Sessions, San Diego, California, 24th-28th June 2011.  View poster

Reiche D et al. Chronic administration of a new dual NEP/ECE inhibitor or lorsartan improves renal function in mice with diabetic nephropathy. Abstract No. 1011-P. American Diabetes Association 71st Scientific Sessions, San Diego, California, 24th-28th June 2011.  View poster

Surman M et al. ALB-127158(a): An MCH₁ receptor antagonist that exhibits weight loss and improvements in insulin sensitivity in diet-induced obese mice. Abstract No. 0108-LB. American Diabetes Association 71st Scientific Sessions, San Diego, California, 24th-28th June 2011.  View poster

Vickers SP et al. The DPP-4 inhibitor linagliptin is weight neutral in the DIO rat but inhibits the weight gain of DIO animals withdrawn from exenatide. Abstract No. 979-P. American Diabetes Association 71st Scientific Sessions, San Diego, California, 24th-28th June 2011.  View poster 

Vickers SP et al. Effect of STZ dose and dosing regimen on the diabetes phenotype of C57BL/6J mice fed a high fat diet. Diabetes Summit, Philadelphia, Pennsylvania, 7th-8th March 2011.  View poster

Henderson AJ et al. Identification of the 5-HT₆ antagonist AMR-SIX-1 for the treatment of obesity. Keystone Symposium, Obesity, Keystone, Colorado, 12th-17th January 2011.  View poster

Grempler R et al. Weight Loss Induced by the Potent and Selective SGLT-2 Inhibitor, BI 10773, is Due to Body Fat Reduction Studies in Dietary-Induced Obese Rats. Abstract No. 1793-P. American Diabetes Association 70th Scientific Sessions, Orlando, Florida, 25th-29th June 2010.  View poster

Cheetham SC et al. Effect of the MCH₁ antagonist, GW803430, on body weight, food and water intake, glucose tolerance, fat pad weight, ex vivo binding and various plasma parameters in dietary-induced obese C57BL/6J mice. Program No. 584.24. Society for Neuroscience Meeting, Washington, DC, 15th-19th November 2008.  View poster

Heal DJ et al. Prevention of antipsychotic-induced weight-gain by the 5-HT₆ agonist, E-6837. Program No. 584.12. Society for Neuroscience Meeting, Washington, DC, 15th-19th November 2008.  View poster

Vickers SP et al. Effect of rimonabant on body weight, glucose tolerance, body composition and lipolysis in fa/fa Zucker rats: A comparison with pair-fed controls. Program No. 584.18. Society for Neuroscience Meeting, Washington, DC, 15th-19th November 2008.  View poster

Jackson HC et al. Effect of chronic administration of topiramate and phentermine alone and in combination in an animal model of dietary induced obesity. Program No. 629.15. Society for Neuroscience Meeting, San Diego, California, 3rd-7th November 2007.  View poster

Shacham S et al. PRX-07034, a potent and selective 5-HT₆ receptor antagonist, reduces food intake and body weight in dietary-induced obese rats. Program No. 62.10. Society for Neuroscience Meeting, Atlanta, Georgia, 14th-18th October, 2006.  View poster

Jackson HC et al. Comparison of the effects of rimonabant and sibutramine in a rat model of dietary induced obesity. Program No. 532.13. Society for Neuroscience Meeting, Washington, DC, 12th-16th November 2005.  View poster

Vickers SP et al. Comparison of the effects of rimonabant, sibutramine and orlistat on acute food intake and in a model of dietary induced obesity in the mouse. Program No. 532.12. Society for Neuroscience Meeting, Washington, DC, 12th-16th November 2005.  View poster

Jackson HC et al. Comparison of the effects of sibutramine and orlistat on body weight, food and water intake and body composition in dietary-induced obese rats.  Program No. 76.19. Society for Neuroscience Meeting, San Diego, California, 23rd-27th October 2004.  View poster